PT  - JOURNAL ARTICLE
AU  - CLAUDE LINASSIER
AU  - DELPHINE CARMIER
AU  - PIERRE COMBE
AU  - BENJAMIN FAIVRE D'ARCIER
AU  - FRANCK BRUYERE
AU  - BERANGERE NARCISO
TI  - Metastatic Renal Cell Carcinoma Treated Sequentially with Multiple VEGF Receptor-targeted Inhibitors – A Case Report
DP  - 2012 Feb 01
TA  - Anticancer Research
PG  - 697--700
VI  - 32
IP  - 2
4099  - http://ar.iiarjournals.org/content/32/2/697.short
4100  - http://ar.iiarjournals.org/content/32/2/697.full
SO  - Anticancer Res2012 Feb 01; 32
AB  - Six targeted agents [sorafenib, sunitinib, temsirolimus, bevacizumab (plus interferon), everolimus and pazopanib] have been approved for the treatment of patients with metastatic renal cell carcinoma. As disease progression is inevitable, most patients will receive several lines of treatment. However, the choice regarding which sequence of drugs to use remains unclear, particularly concerning the drug class, i.e. those targeting the vascular endothelial growth factor (receptor) [VEGF(R)] pathway versus those acting on the mammalian target of rapamycin pathway. There appears to be no absolute crossresistance between tyrosine kinase inhibitors (TKIs) acting on the VEGF(R) pathway, and there have been numerous reports of two TKIs being successfully used in sequence. We report the case of a 63-year-old woman who responded for 24 months to three successive lines of treatment with different TKIs (sunitinib, axitinib and sorafenib). This suggests that TKIs targeting VEGFR should be considered as individual drugs and not as a single class.